Results 101 to 110 of about 15,844 (160)

FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies. [PDF]

Cancers (Basel)
Xin X, Miao R.
europepmc   +1 more source

HScore as a diagnostic tool in ERBB2 equivocal (immunohistochemistry 2+) breast cancer. [PDF]

Lab Med
Alsebai T, Swied MY, Cossyleon R, Robinson K, Delfino K, Gao J, Rao K.   +6 more
europepmc   +1 more source

Premenopausal Patients With Clinically Aggressive Metastatic Breast Cancer Successfully Treated With a First-Line Palbociclib-Containing Regimen: Two Cases and Literature Review. [PDF]

Cancer Rep (Hoboken)
Fu PA, Hsu YC, Hsu HP, Lin TC, Chung WP.
europepmc   +1 more source

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysis. [PDF]

Breast
Yang Y, Pan L, Zhou W, Shao Z.
europepmc   +1 more source

Association of statin use with pathological complete response in postmenopausal patients with hormone receptor-positive breast cancer. [PDF]

Sci Rep
Ersoy M.
europepmc   +1 more source

Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer. [PDF]

J Comp Eff Res
Watkins C, Simon C, Martin P, Leadley R, Redhead G, Neuberger E, Bartley K.   +6 more
europepmc   +1 more source

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer. [PDF]

Clin Cancer Res
Casak SJ, Zhang Y, Song C, Mishra-Kalyani PS, Tang S, Auth D, de Claro RA, Pazdur R, Lemery SJ.   +8 more
europepmc   +1 more source

Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer. [PDF]

Breast Cancer Res Treat
Zelizer S, Gallagher GB, Gonen M, Dang C, Modi S, Chandarlapaty S, Drago JZ.   +6 more
europepmc   +1 more source

Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors. [PDF]

Sci Rep
Torrisi R, Giordano L, Pancetti S, Carnaghi C, Basilico V, Palumbo R, Gerosa R, Saltalamacchia G, Sanò MV, Santoro A, Fernandes B.   +10 more
europepmc   +1 more source